Date:7/29/2009

530,991 Stock based compensation 37,616 4,789,025 Other non-cash items - 1,383,537 Net changes in non-cash working capital 1,182,343 2,689,901 ----------------------------------------------------------- (7,224,814) (97,840,700) ----------------------------------------------------------- INVESTING ACTIVITIES Capital assets (58,745) (817,093) Purchase of short-term investments (252,196) (49,416,864) Redemption of short-term investments 9,000,000 48,998,380 Investment in BCY LifeSciences Inc. - 464,602 Investment in Transition Therapeutics Inc. - 2,532,343 ----------------------------------------------------------- 8,689,059 1,761,368 ----------------------------------------------------------- FINANCING ACTIVITIES Proceeds from exercise of warrants and stock options - 15,674,153 Proceeds from acquisition of private company - 1,800,120 Proceeds from private placements - 38,137,385 Proceeds from public offerings - 52,451,026 ----------------------------------------------------------- - 108,062,684 ----------------------------------------------------------- Increase in cash and cash equivalents during the period 1,464,245 11,983,352 Cash and cash equivalents, beginning of the period 6,715,096 - ----------------------------------------------------------- Cash and cash equivalents, end of the period 8,179,341 11,983,352 ---------------------------------------------
'/>"/>

SOURCE Oncolytics Biotech Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference